PROGRAM MANAGER: Jos Cenens, Ph.D.
Licensing, product acquisition, contract research, proof of concept leading to scale-up to manufacturing, joint development, supplier agreement
Phase 1 – Proof of concept in 12 months Phase 2 – Commercial development
All financial details are to be negotiated
SOLUTION PROVIDER HELP DESK:
NineSigma, representing a global health company, invites proposals for a system that can edit the genome of mammalian cells, particularly CHO-K1 or HEK293 derived cell lines. Ideally the system should be useable in both higher and lower eukaryotes (such as S. pombe, S. pastoris, S. cerevisiae). The desired system must be free of 3rd party background intellectual property and have the freedom to operate outside of the core technology patents in the genome editing and gene expression control space.
NineSigma’s client wants to engineer suitable host cell lines into novel phenotypes. This will involve gene knock-outs, insertions of genes of either inactive pathways or creating pathways that do not exist in the current host cell lines. Furthermore, they want to control gene transcription of endogenous and exogenously added genes (e.g., for synthetic biology or for generating induced pluripotent stem cells). Of particular interest are CHO-K1 or HEK293-derived cell lines and the application of transcriptional control over genes in different eukaryotic cell types like S. pombe, S. pastoris, and S. cerevisiae.
The licensing terms for the commercial generation of new engineered cGMP-ready host cell lines using CRISPR-Cas9 system are expensive, so NineSigma’s client wants to identify an alternative system for editing the genome of eukaryotic cells.
The proposed gene editing system needs convincing proof that the technology is viable and capable to meet the specifications.
Anticipated Project Phases or Project Plan The client will review submitted proposals and possibly ask clarifying questions before selecting the suitable candidates for collaboration. During the selection process, the client may execute non-disclosure agreements (NDA) with selected respondent(s), seek further information disclosure, and discuss specific development targets. The client will execute necessary agreement(s) with the selected respondent(s) and move to the commercial development phase.
The successful technology will be capable to perform the functions associated with the CRISPR-Cas9 system:
Possible approaches might include, but are not limited to:
The following approaches are not of interest:
To respond, please make sure you are registered in NineSights, as it will prompt you to log in. Then, use the Response options at the top or bottom of the page. You may submit supplemental files in addition to your completed response form.
Appropriate responses will use the response form and address the following:
Other Request information includes:
APPROPRIATE RESPONSES TO THIS REQUEST
Responses from companies (small to large), academic researchers, other research institutes, consultants, venture capitalists, entrepreneurs, or inventors are welcome. For example:
You represent a company that have demonstrated a proof of concept of a CRISPR alternative and are looking for a partner to commercialize it .
You represent a university research department that has promising results with a novel gene editing technology and is looking for financial support to finalize the development.